What proportion of regorafenib-treated patients developed hypothyroidism requiring hormone replacement in placebo-controlled phase III trials?

In placebo-controlled phase III trials, approximately 4.6% of patients treated with Stivarga (regorafenib) developed hypothyroidism requiring hormonal replacement treatment.